| Bioactivity | Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer[1][2][3][4]. |
| Invitro | Ladiratuzumab vedotin (LIV-1+ 细胞) 通过 ATF6 的激活以及 IRE1 和 eIF2a 的磷酸化激活内质网应激反应[3]。Ladiratuzumab vedotin (LIV-1+ 细胞) 将 ATP 和 HMGB1 释放到上清液中 (ICD 标志)[3]。Ladiratuzumab vedotin (0-100 ng/mL) 对 MCF-7 细胞显示出细胞毒活性[4]。Ladiratuzumab vedotin (1 μg/mL，24 小时) 内化、运输到溶酶体，并破坏 MCF-7 细胞中的微管网络[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Ladiratuzumab vedotin 相关抗体: Cell Viability Assay[4] Cell Line: |
| In Vivo | Ladiratuzumab vedotin (3 mg/kg，腹腔注射，每 4 天一次) 在 MCF-7 乳腺癌细胞异种移植模型中导致肿瘤消退[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1629760-29-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rizzo A, et al. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. [2]. Jane Lowe Meisel, et al. Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). Journal of Clinical Oncology. 2022 40:16_suppl, TPS1127-TPS1127. [3]. Anthony T. Cao, et al. Abstract 2742: Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Res (2018) 78 (13_Supplement): 2742. [4]. Sussman D, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. |